natgillin/translations-raw huggingface dataset:
The aim of treatment is to maintain your haemoglobin level between 10 and 12 g/dL as a higher haemoglobin level may increase the risk of blood clots and death. 
Namen zdravljenja je ohranjati vašo raven hemoglobina med 10 in 12 g/dl, saj višje ravni hemoglobina lahko povečajo tveganje za krvne strdke in smrt.
After single doses (20 000 to 160 000 IU subcutaneously) of epoetin alfa, a dose-dependent response was observed for the pharmacodynamic markers investigated including: reticulocytes, RBCs, and haemoglobin. 
Po enkratnem odmerjanju (20.000 do 160.000 i.e. subkutano) epoetina alfa so opazili od odmerka odvisen odziv preučevanih farmakodinamičnih kazalcev, vključno z retikulociti, eritrociti in hemoglobinom.
Patients were assigned to epoetin alfa treatment targeting a maintenance haemoglobin level of 13.5 g/dL (higher than the recommended haemoglobin concentration level) or 11.3 g/dL. 
Bolnike so razporedili na zdravljenje z epoetinom alfa s ciljem ohranjati raven hemoglobina 13,5 g/l (nad priporočeno koncentracijo hemoglobina) ali 11,3 g/l.
In order to ensure optimum response to epoetin zeta, adequate iron stores should be assured and iron supplementation should be administered if necessary (see section 4.4). 
Da je odziv na epoetin zeta optimalen, je treba poskrbeti za ustrezne zaloge železa in po potrebi dodajati železo (glejte poglavje 4.4).
In a prospective, randomised, double-blind, placebo-controlled trial conducted in 375 anaemic patients with various non-myeloid malignancies receiving non-platinum chemotherapy, there was a significant reduction of anaemia-related sequelae (e.g. fatigue, decreased energy, and activity reduction), as measured by the following instruments and scales: Functional Assessment of Cancer TherapyAnaemia (FACT-An) general scale, FACT-An fatigue scale, and Cancer Linear Analogue Scale (CLAS). 
V prospektivnem, randomiziranem, dvojno slepem s placebom kontroliranem preskušanju so pri 375 slabokrvnih bolnikih z različnimi nemieloidnimi malignostmi, ki so prejemali kemoterapijo brez platine, ugotovili signifikantno zmanjšanje z anemijo povezanih posledic (npr. utrujenosti, zmanjšane energije in zmanjšane aktivnosti), kot se jih meri s pomočjo naslednjih instrumentov in meril: splošna merila za funkcionalno oceno terapije raka - anemija (FACT-An - ''Functional Assessment of Cancer Therapy-Anaemia''), FACT-An merila utrujenosti, in linearna analogna skala za rak (CLAS - ''Cancer
Epoetin zeta is not approved in the management of anaemia associated with hepatitis C. 
Epoetin zeta ni odobren za zdravljenje anemije, povezane s hepatitisom C.
In studies to explore extending the dosing interval (40 000 IU once weekly and 80 000, 100 000, and 120 000 IU biweekly), a linear but non-dose-proportional relationship was observed between mean Cmax and dose, and between mean AUC and dose at steady state. 
V študijah, v katerih so preučevali podaljšanje intervala odmerjanja (40.000 i.e. enkrat na teden ter 80.000, 100.000 in 120.000 i.e. vsaka dva tedna), so opazili z odmerkom nesorazmerno linearno razmerje med povprečno vrednostjo Cmax in odmerkom ter med povprečno vrednostjo AUC in odmerkom v stanju dinamičnega ravnovesja.
• If there is a medical need to reduce the time before your operation, you will be given a daily dose of 300 IU/kg for up to ten days before surgery, on the day of surgery and for four days immediately afterwards. 
• Če je iz zdravstvenega razloga treba čas pred vašo operacijo skrajšati, boste prejemali dnevni odmerek 300 i.e./kg največ 10 dni pred operacijo, na dan operacije in še 4 dni takoj po operaciji.
The recommended dose is Retacrit 600 IU/kg administered subcutaneously weekly for three weeks (days -21, -14 and -7) prior to surgery and on the day of surgery. 
Priporočeni odmerek zdravila Retacrit je 600 i.e./kg, ki ga damo subkutano enkrat na teden, tri tedne (21., 14. in 7. dan) pred kirurškim posegom in na dan kirurškega posega.
The desired haemoglobin concentration level in two studies was >13 g/dL (8.1 mmol/L); in the remaining three studies it was 12 to 14 g/dL (7.5 to 8.7 mmol/L). 
Ciljna koncentracija hemoglobina je bila v dveh študijah > 13 g/dl (8,1 mmol/l), v preostalih treh študijah pa od 12 do 14 g/dl (7,5 to 8,7 mmol/l).
What Retacrit looks like and contents of the pack 
Izgled zdravila Retacrit in vsebina pakiranja
A rise in haemoglobin of greater than 2 g/dL over a four week period should be avoided. 
Treba se je izogibati povečanju vrednosti hemoglobina za več kot 2 g/dl v času 4 tednov.
Caution should be exercised with escalation of Retacrit doses in patients with chronic renal failure since high cumulative epoetin doses may be associated with an increased risk of mortality, serious cardiovascular and cerebrovascular events. 
Pri višanju odmerkov zdravila Retacrit pri bolnikih s kronično ledvično odpovedjo je potrebna previdnost, ker so kumulativni odmerki epoetina lahko povezani s povečanim tveganjem za smrt ter resne kardiovaskularne in cerebrovaskularne dogodke.
Epoetin zeta should be used with caution in patients with epilepsy, history of seizures, or medical conditions associated with a predisposition to seizure activity such as CNS infections and brain metastases. 
Epoetin zeta je treba previdno uporabljati pri bolnikih z epilepsijo, epileptičnimi napadi v anamnezi ali zdravstvenimi stanji, povezanimi z nagnjenostjo k epileptični aktivnosti, kot so okužbe CŽS in možganske metastaze.
In addition, there was no statistical difference between the proportion of patients requiring pRBC transfusions between the Epoetin alfa group and placebo. 
Poleg tega ni bilo statistične razlike med deležem bolnikov, ki so potrebovali transfuzije koncentriranih rdečih krvničk, v skupini, ki se je zdravila z epoetinom alfa, in skupini, ki se je zdravila s placebom.
In chronic renal failure patients, the half-life of intravenously administered erythropoietin is slightly prolonged, approximately 5 hours, compared to healthy subjects. 
Pri bolnikih s kronično ledvično odpovedjo je razpolovni čas intravensko danega eritropoetina v primerjavi z zdravimi preskušanci nekoliko podaljšan in znaša približno 5 ur.
Patients should be monitored closely to ensure that the lowest approved effective dose of Retacrit is used to provide adequate control of anaemia and of the symptoms of anaemia whilst maintaining a haemoglobin concentration below or at 12 g/dL (7.5 mmol/L). 
Bolnike morate skrbno nadzorovati, da bi zagotovili uporabo najnižjega odobrenega učinkovitega odmerka zdravila Retacrit za primeren nadzor anemije in simptomov anemije, pri čemer naj koncentracija hemoglobina ostane pod ali pri 12 g/dl (7,5 mmol/l).
Prolonged vigorous shaking may damage the product. 
Dolgotrajnejše močnejše stresanje lahko poškoduje zdravilo.
Available evidence suggests patients with haematological malignancies and solid tumours respond equivalently to epoetin alfa therapy, and that patients with or without tumour infiltration of the bone marrow respond equivalently to epoetin alfa therapy. 
Razpoložljivi dokazi kažejo, da se bolniki s hematološkimi malignimi obolenji in čvrstimi tumorji enakovredno odzivajo na zdravljenje z epoetinom alfa ter da se na zdravljenje z epoetinom alfa enakovredno odzivajo tudi bolniki z infiltracijo tumorja v kostni mozeg in brez nje.
Do not use this medicine after the expiry date which is stated on the box and on the label after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na nalepkipo oznaki EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca..
If the patient loses response or haemoglobin concentration drops by ≥1 g/dL upon dose reduction the dose should be increased by one dosing step. 
Če po zmanjšanju odmerka bolnik postane neodziven ali če koncentracija hemoglobina pade za ≥ 1 g/dl, je treba odmerek povečati za en odmerni korak.
• Hold the pre-filled syringe by the body of the syringe with the covered needle pointing upward. 
• Napolnjeno injekcijsko brizgo držite za telo igle tako, da je pokrita igla usmerjena navzgor.
The reported risk of these TVEs should be carefully weighed against the benefits to be derived from treatment with epoetin zeta particularly in patients with pre-existing risk factors for TVE, including obesity and prior history of TVEs (e.g., deep venous thrombosis, pulmonary embolism, and cerebral vascular accident). 
Poročano tveganje za TVE je treba skrbno pretehtati glede na pričakovano korist zdravljenja z epoetinom zeta, predvsem pri bolnikih z obstoječimi dejavniki tveganja za TVE, vključno z debelostjo in TVE v anamnezi (npr. globoka venska tromboza, pljučna embolija in cerebrovaskularni dogodki).
Adult haemodialysis patients 
Odrasli hemodializni bolniki
Comparable intensity of chemotherapy in the epoetin alfa and placebo groups in the chemotherapy trials was demonstrated by a similar area under the neutrophil time curve in patients treated with epoetin alfa and placebo-treated patients, as well as by a similar proportion of patients in groups treated with epoetin alfa and placebo-treated groups whose absolute neutrophil counts fell below 1 000 and 500 cells/μL. 
V skupini z epoetinom alfa in v skupini s placebom v preskušanjih pri bolnikih na kemoterapiji so dokazali primerljivo intenzivnost kemoterapije s podobno površino pod krivuljo števila nevtrofilcev v odvisnosti od časa pri bolnikih, ki so se zdravili z epoetinom alfa, in pri bolnikih, ki so prejemali placebo, kot tudi s podobnim deležem bolnikov v skupini, ki se je zdravila z epoetinom alfa, in skupini, ki je prejemala placebo, pri katerih je absolutno število nevtrofilcev padlo pod 1.000 oziroma pod 500 celic/μl.
• Do not pull back on the plunger at any time. 
• Bata nikdar ne povlecite nazaj.
Moreover, in patients with a baseline haemoglobin of >13 g/dL (>8.1 mmol/L), the possibility that epoetin zeta treatment may be associated with an increased risk of postoperative thrombotic/vascular events cannot be excluded. 
Pri bolnikih z izhodiščno koncentracijo hemoglobina > 13 g/dl (> 8,1 mmol/l) ni mogoče izključiti možnosti, da je zdravljenje z epoetinom zeta lahko povezano s povečanim tveganjem za pooperativne trombotične žilne dogodke.
One pack contains 1, 4 or 6 pre-filled syringes with or without a needle guard or needle-trap device. 
Eno pakiranje vsebuje 1, 4 ali 6 napolnjenih injekcijskih brizg s pripomočkom za zaščito igle ali brez njega ali z varovalnim nastavkom Needle-Trap.
In a study comparing the 150 IU/kg, 3 times-per-week and 40 000 IU, once-weekly dosing regimens in healthy subjects and in anaemic cancer subjects the time profiles of changes in percent reticulocytes, haemoglobin, and total red blood cells were similar between the two dosing regimens in both healthy and anaemic cancer subjects. 
V študiji, v kateri so primerjali režim odmerjanja 150 i.e./kg trikrat na teden in 40.000 i.e. enkrat na teden pri zdravih preskušancih in pri anemičnih preskušancih z rakom, so bili časovni profili sprememb odstotka retikulocitov, vrednosti hemoglobina in celokupnega števila rdečih krvničk podobni med obema režimoma odmerjanja pri zdravih preskušancih in pri anemičnih preskušancih z rakom.
An open-label, parallel-group trial in non-iron deficient adult subjects with a pretreatment haemoglobin of ≥ 10 to ≤ 13 g/dL who were scheduled for major orthopaedic hip or knee surgery compared epoetin alfa 300 IU/kg subcutaneously daily for 10 days prior to surgery, on the day of surgery and for four days after surgery to epoetin alfa 600 IU/kg subcutaneously once weekly for 3 weeks prior to surgery and on the day of surgery. 
V odprtem preskušanju z vzporednima skupinama pri odraslih osebah brez pomanjkanja železa in z vrednostmi hemoglobina pred zdravljenjem > 10 do ≤ 13 g/dl, ki so imeli načrtovan večji ortopedski kirurški poseg na kolku ali kolenu, so primerjali epoetin alfa 300 i.e./kg subkutano enkrat na dan v obdobju 10 dni pred kirurškim posegom, na dan kirurškega posega in 4 dni po kirurškem posegu, z epoetinom alfa 600 i.e./kg subkutano enkrat na teden v obdobju 3 tednov pred kirurškim posegom in na dan kirurškega posega.
These include venous and arterial thrombosis and embolism (including some with fatal outcomes), such as deep venous thrombosis, pulmonary emboli, retinal thrombosis, and myocardial infarction. 
Ti vključujejo vensko in arterijsko trombozo ter embolijo (vključno z nekaj smrtnimi izidi), kot so globoka venska tromboza, pljučna embolija, tromboza mrežnice in miokardni infarkt.
Retacrit is indicated in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements. 
Zdravilo Retacrit je indicirano pri odraslih, ki prejemajo kemoterapijo zaradi čvrstih tumorjev, malignega limfoma ali multiplega mieloma, in za katere je transfuzija glede na splošno stanje bolnika tvegana (npr. kardiovaskularni status, anemičnost ob začetku kemoterapije), za zdravljenje anemije in zmanjšanje potrebe po transfuzijah.
Epoetin zeta should be used with caution in patients with chronic liver failure. 
Epoetin zeta je treba previdno uporabljati pri bolnikih s kronično odpovedjo jeter.
Patients scheduled for major elective orthopaedic surgery should receive adequate antithrombotic prophylaxis, as thrombotic and vascular events may occur in surgical patients, especially in those with underlying cardiovascular disease. 
Bolniki, naročeni na večji elektivni ortopedski kirurški poseg, morajo prejeti ustrezno antiagregacijsko profilakso, zaradi tveganja za trombotične in žilne dogodke pri kirurških bolnikih, še posebej pri tistih z boleznijo srca in ožilja.
Moreover, epoetin alfa doses of 75 to 150 IU/kg per week have been shown to maintain haematocrits of 36 to 38% for up to six months. 
Pokazalo se je tudi, da epoetin alfa v odmerkih 75 do 150 i.e./kg na teden ohranja koncentracije hematokrita v razponu od 36 do 38 % do šest mesecev.
At the time of clinical data cutoff, the median progression free survival (PFS) per investigator assessment of disease progression was 7.4 months in each arm (HR 1.09, 95% CI: 0.99, 1.20), indicating the study objective was not met. 
V času zajema kliničnih podatkov je bilo mediano preživetje brez napredovanja bolezni (PFS - progression-free survival) po raziskovalčevi oceni napredovanja bolezni 7,4 meseca v obeh skupinah (HR 1,09, 95 % IZ: 0,99; 1,20), kar kaže, da cilja študije niso dosegli.
Dose (IU/kg given 3 times per week) 
Odmerek (i.e./kg, trikrat tedensko)
Retacrit contains the active substance epoetin zeta - a protein that stimulates the bone marrow to produce more red blood cells which carry haemoglobin (a substance that transports oxygen). 
Zdravilo Retacrit vsebuje učinkovinoepoetin zeta-beljakovino, ki stimulira kostni mozeg, da tvori več rdečih krvnih celic, ki prenašajo hemoglobin (snov, ki prenaša kisik).
Hypersensitivity reactions, including cases of rash (including urticaria), anaphylactic reactions, and angioneurotic oedema have been reported (see section 4.4). 
Poročali so o preobčutljivostnih reakcijah, vključno s primeri izpuščaja (vključno z urtikarijo), anafilaktičnimi reakcijami in angionevrotičnim edemom (glejte poglavje 4.4).
• Flu-like symptoms, such as headache, aches and pains in the joints, feeling of weakness, chills, 
• Gripi podobni simptomi, kot so glavobol, bolečine v sklepih, občutek šibkosti, mrzlica, utrujenost in omotica.
Where intravenous access is not readily available (patients not yet undergoing dialysis and peritoneal dialysis patients) Retacrit may be administered as a subcutaneous injection. 
Kadar intravenski dostop ni takoj na razpolago (bolniki, ki se še ne zdravijo s hemodializo, in bolniki na peritonealni dializi), zdravilo Retacrit lahko dajemo z injiciranjem pod kožo.
The desired haemoglobin concentration range was 9.6 to 11.2 g/dL. 
Želeni razpon koncentracije hemoglobina je bil 9,6 do 11,2 g/dl.
Retacrit is prescribed to stimulate your bone marrow to produce more red blood cells. 
Zdravilo Retacrit predpisujemo za spodbujanje kostnega mozga k tvorbi več rdečih krvnih celic.
Epoetin alfa has been shown to stimulate red blood cell production in order to augment autologous blood collection, and to limit the decline in haemoglobin in adult patients scheduled for major elective surgery who are not expected to predeposit their complete perioperative blood needs. 
Dokazali so, da epoetin alfa spodbuja nastajanje rdečih krvničk, kar poveča količino odvzete avtologne krvi in zmanjša upad koncentracije hemoglobina pri odraslih bolnikih, naročenih na večji kirurški poseg, pri katerih ni pričakovati, da bodo deponirali kri za vse svoje potrebe ob operaciji.
Each pack contains 1 or 6 pre-filled syringes. 
Vsako pakiranje vsebuje 1 ali 6 napolnjenih injekcijskih brizg.
• Retacrit is used in moderately anaemic adults about to have major orthopaedic surgery (for example hip or knee replacement operations), to reduce the potential need for blood transfusions. 
- Zdravilo Retacrit se uporablja za zmerno slabokrvne odrasle, naročene na večji ortopedski kirurški poseg (na primer operacije za zamenjavo kolka ali kolena), da bi zmanjšali morebitno potrebo po transfuziji krvi.
These patients responded to epoetin alfa therapy in a manner similar to that observed in patients on dialysis. 
Ti bolniki so se na zdravljenje z epoetinom alfa odzvali podobno kot bolniki na dializi.
How to use Retacrit 
Kako uporabljati zdravilo Retacrit
• Your doctor will maintain your haemoglobin level between 10 and 12 g/dL as a high haemoglobin level may increase the risk of blood clots and death. 
• Zdravnik bo ohranjal vašo raven hemoglobina med 10 in 12 g/dl, saj lahko visoka raven hemoglobina poveča tveganje za krvne strdke in smrt.
Retacrit is not approved in the management of anaemia associated with hepatitis C. 
Zdravilo Retacrit ni odobreno za zdravljenje anemije, povezane s hepatitisom C.
• in adults on haemodialysis or peritoneal dialysis. 
- pri odraslih na hemodializi ali peritonealni dializi.
In patients with a poor haemoglobin response to ESA, alternative explanations for the poor response should be considered (see sections 4.4 and 5.1). 
Pri bolnikih s slabim odzivom hemoglobina na ESA je treba razmisliti o možnih drugih razlagah za slab odziv na zdravljenje (glejte poglavje 4.4 in 5.1).
In clinical trials, an increased risk of death and serious cardiovascular events was observed when ESAs were administered to achieve a haemoglobin concentration level of greater than 12 g/dL (7.5 mmol/L). 
V kliničnih preskušanjih so opazili povečano tveganje za smrt in resne kardiovaskularne dogodke, kadar so ESA dajali, da bi dosegli koncentracijo hemoglobina, ki presega 12 g/dl (7,5 mmol/l).
Each pack contains 1, 4 or 6 pre-filled syringes. 
Vsako pakiranje vsebuje 1, 4 ali 6 napolnjenih injekcijskih brizg.
Epoetin alfa was administered at 75 IU/kg/week intravenously in 2 or 3 divided doses post-dialysis, titrated by 75 IU/kg/week at intervals of 4 weeks (up to a maximum of 300 IU/kg/week), to achieve a 1 g/dL/month increase in haemoglobin. 
Epoetin alfa so injicirali intravensko v odmerku 75 i.e./kg/teden v 2 ali 3 razdeljenih odmerkih po dializi, ki so ga v 4-tedenskih intervalih titrirali po 75 i.e./kg/teden (do največ 300 i.e./kg/teden) z namenom doseči povečanje koncentracije hemoglobina za 1 g/dl/mesec.
• If you are a cancer patient, be aware that use of Retacrit may be associated with shorter survival and a higher death rate in head and neck, and metastatic breast cancer patients who are receiving chemotherapy. 
• Če ste bolnik z rakom, morate vedeti, da je uporaba zdravila Retacrit pri bolnikih z rakom glave in vratu ter bolnikih z metastatskim rakom dojk, ki prejemajo kemoterapijo, lahko povezana s krajšim preživetjem in višjo stopnjo smrti.
Antibody-mediated pure red cell aplasia has been very rarely reported in <1/10 000 cases per patient year after months to years of treatment with epoetins (see section 4.4). 
:Zelo redko (pri < 1/10.000 primerov na bolnika-leto) so poročali o pojavu čiste aplazije rdečih krvnih celic, povzročene s protitelesi, po več mesecih ali letih zdravljenja z epoetini (glejte poglavje 4.4).
Particular attention should be paid to sudden stabbing migraine-like headaches as a possible warning signal (see section 4.4). 
Treba je biti pozoren na nenaden pojav migreni podobnih glavobolov z zbadanjem, ki so lahko morebitni opozorilni znak (glejte poglavje 4.4).
Sixteen percent of epoetin alfa 300 IU/kg, 23% of epoetin alfa 100 IU/kg and 45% of placebo-treated patients required transfusion. 
Transfuzijo je potrebovalo 16 % bolnikov, ki so se zdravili z epoetinom alfa 300 i.e./kg, 23 % bolnikov, ki so se zdravili z epoetinom alfa 100 i.e./kg, in 45 % bolnikov, ki so se zdravili s placebom.
A patient-level data analysis has also been performed on more than 13 900 cancer patients (chemo-, radio-, chemoradio-, or no therapy) participating in 53 controlled clinical trials involving several epoetins. 
Pri več kot 13.900 bolnikih z rakom (kemoterapija, radioterapija, kemo-radioterapija ali nezdravljeni), ki so sodelovali v 53 kontroliranih kliničnih preskušanjih, v katerih so uporabljali različne epoetine, je bila narejena analiza podatkov o bolnikih.
This medicine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium-free'. 
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni ''brez natrija''.
Further pharmacodynamic studies explored 40 000 IU once weekly versus 150 IU/kg 3 times per week. 
V nadaljnjih farmakodinamičnih študijah so preučevali režim odmerjanja 40.000 i.e. enkrat na teden v primerjavi s 150 i.e./kg trikrat tedensko.
Particular attention should be paid to sudden stabbing migraine-like headaches as a possible warning signal (see section 4.8). 
Treba je biti pozoren na nenaden pojav migreni podobnih glavobolov z zbadanjem, ki so lahko morebitni opozorilni znak (glejte poglavje 4.8).
It is recommended that the platelet count is regularly monitored during the first 8 weeks of therapy. 
Prvih osem tednov zdravljenja je priporočljivo redno nadzorovanje števila trombocitov.
The solution contains 3 333 IU epoetin zeta per ml. 
Raztopina vsebuje 3.333 i.e. epoetina zeta na ml.
In clinical trials conducted in patients with CRF not on dialysis treated with epoetin alfa, the average duration of therapy was nearly five months. 
V kliničnih preskušanjih pri bolnikih s kronično ledvično odpovedjo, ki še ne zdravijo z dializo, a se zdravijo z epoetinom alfa, je zdravljenje povprečno trajalo skoraj pet mesecev.
For chronic renal failure patients, iron supplementation (elemental iron 200 to 300 mg/day orally for adults and 100 to 200 mg/day orally for paediatrics) is recommended if serum ferritin levels are below 100 ng/mL. 
Pri bolnikih s kronično ledvično okvaro se priporoča dodajanje železa (elementarno železo 200 do 300 mg/dan peroralno za odrasle in 100 do 200 mg/dan peroralno za pediatrično populacijo), če imajo nivoje feritina v serumu pod 100 ng/ml.
Shunt thrombosis have occurred in haemodialysis patients, especially in those who have a tendency to hypotension or whose arteriovenous fistulae exhibit complications (e.g. stenoses, aneurysms, etc.). 
Pri bolnikih na hemodializi so se pojavile tromboze šanta, še posebej pri tistih, ki so nagnjeni k hipotenziji, ali pri bolnikih, pri katerih se na arteriovenskih fistulah kažejo zapleti (npr. stenoze, anevrizme).
Anaemia in chronic renal failure patients before initiation of dialysis or on peritoneal dialysis 
Anemija pri bolnikih s kronično ledvično okvaro pred začetkom dialize ali na peritonealni dializi
In most anaemic subjects with cancer receiving cyclic chemotherapy CL/F was lower after subcutaneous doses of 40 000 IU once weekly and 150 IU/kg, 3 times per week compared with the values for healthy subjects. 
Pri večini anemičnih preskušancev z rakom, ki so prejemali ciklično kemoterapijo, je bil CL/F po subkutanih odmerkih 40.000 i.e. enkrat na teden in 150 i.e./kg trikrat na teden manjši kot pri zdravih preskušancih.